Saturday 17 October 2026 Export SLDB’s income statement to Excel — free account

Solid Biosciences Inc.

Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.

5.53 0.21 −3.66%

Follow SLDB

Alert me

Market cap: $615.5M
P/E: 0.0×
Fwd P/E: −2.4×
Dividend yield: —
F-score: n/a
Altman Z: −2.87
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.66

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	4	3	20	—	—	—	—	—	—	—	—

Insider Ownership 39.12%

Capital & Financial Ratios $m

Market Cap 615.48

Revenue 11.25

Net Income (207.10)

Free Cash Flow (187.72)

Net Debt (378.32)

Current Ratio 13.82

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.37)

P/S ratio 70.64

P/B ratio 2.12

Past 5Y EPS Growth —

This Y EPS Growth 12.61%

Next Y EPS Growth 2.65%

Next Y revenue growth (89.13%)

Next 5Y EPS Growth 17.43%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 90.77%

10-year low 10-year high

P/B against its own 10 years 60.45%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	124	149	189	378
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	130	157	205	395

	2023	2024	2025	Q'26
Payables	2	4	3	4
ST’ Debt	—	—	—	—
Other	0	3	9	4
	15	30	33	29

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	6.39%	(5.26%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	2	6	—	0	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(47)	(53)	—	—	—
’25	(32)	(37)	(33)	(54)	(156)
’24	(25)	(21)	(24)	(30)	(100)
’23	(28)	(27)	(18)	(21)	(94)
’22	(27)	(16)	(20)	(34)	(98)
’21	(21)	(17)	(18)	(21)	(78)
’20	(29)	(13)	(16)	1	(57)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(47)	(53)	—	—	—
’25	(32)	(38)	(34)	(54)	(157)
’24	(25)	(22)	(24)	(30)	(101)
’23	(29)	(28)	(18)	(21)	(96)
’22	(27)	(17)	(21)	(35)	(100)
’21	(21)	(17)	(19)	(22)	(79)
’20	(30)	(13)	(16)	1	(57)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.52)	(0.38)	—	—	—
’25	(0.59)	(0.42)	(0.48)	(0.53)	(1.99)
’24	(0.64)	(0.61)	(0.79)	(1.00)	(3.06)
’23	(1.54)	(1.25)	(1.05)	(1.00)	(4.83)
’22	(3.30)	(3.30)	(2.71)	(0.68)	(10.10)
’21	(2.85)	(2.55)	(2.40)	(2.55)	(10.19)
’20	(8.40)	(5.85)	(6.60)	(4.65)	(25.49)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	102.45	41.25	28.95	23.85	5.21	1.81	3.85	2.41	Analyst estimates 2026–2028 Powerpack
	High	—	—	822.60	492.75	123.60	173.70	27.53	8.20	15.05	7.37
People
People	Employees	60	60	111	121	70	104	87	88	100	121
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.13	0.09	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	14	8	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	100.00	100.00	—	—	—
	EBT	(24)	(53)	(75)	(117)	(88)	(72)	(86)	(96)	(125)	(174)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(530.01)	(1,062.28)	0.00	0.00	0.00
	Net income	(24)	(53)	(75)	(117)	(88)	(72)	(86)	(96)	(125)	(174)
	Depreciation	1	1	1	3	4	4	3	0	(1)	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	1.91	0.95	0.00	0.00	0.00
	Earnings	(209.78)	(43.18)	(33.73)	(43.63)	(25.49)	(10.19)	(10.10)	(4.83)	(3.06)	(1.99)
	Cash flow	(177.58)	(47.48)	(31.64)	(34.50)	(16.35)	(10.92)	(11.51)	(4.74)	(2.45)	(1.79)
	Capex	(3.46)	(2.50)	(3.50)	(1.63)	(0.26)	(0.18)	(0.28)	(0.08)	(0.02)	(0.01)
	Free cash flow	(181.04)	(49.98)	(35.15)	(36.13)	(16.61)	(11.10)	(11.79)	(4.81)	(2.47)	(1.80)
	Book value	(334.39)	(65.09)	56.42	29.79	38.15	29.25	24.87	6.36	3.36	2.06
	Shares, m	0	1	2	3	3	7	9	20	41	88
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	—	—	—
	P/S	—	—	—	—	—	13.72	4.25	—	—	—
	P/B	—	—	—	—	—	0.90	0.23	—	—	—
	EV/Sales	—	—	—	—	—	(1.52)	(14.60)	—	—	—
	EV/FCF	—	—	—	—	—	0.26	1.64	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(20)	(43)	(70)	(93)	(57)	(78)	(98)	(94)	(100)	(156)
	Capex	0	(2)	(8)	(4)	(1)	(1)	(2)	(2)	(1)	(1)
	Free cash flow	(21)	(45)	(78)	(97)	(57)	(79)	(100)	(96)	(101)	(157)
Balance, $m
Balance, $m	Working capital	33	59	116	68	134	199	197	115	127	172
	Total debt	—	—	1	1	1	0	2	1	—	—
	Net debt	(38)	(69)	(122)	(83)	(154)	(207)	(212)	(122)	(149)	(189)
	Shareholders’ equity	(38)	(59)	125	80	132	208	212	126	137	180
Returns, %
Returns, %	ROA	(35.77)	(67.31)	(69.32)	(96.45)	(64.30)	(35.78)	(34.91)	(45.16)	(70.53)	(82.78)
	ROIC	0.00	0.00	(1,322.09)	0.00	0.00	(6,228.79)	0.00	(1,598.96)	0.00	0.00
	ROE	59.61	80.95	(226.92)	(114.24)	(83.24)	(42.43)	(40.96)	(56.79)	(94.57)	(109.90)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AVTX Avalo Therapeutics, Inc.	$644.1M	— (loss-making)	— (loss-making)	−70.14% (below 0%: shrinking)	n/m	+75.70% (above 0%: growing)	55.73%	0.00%	Compare
WVE WAVE Life Sciences Ltd.	$628.6M	— (loss-making)	— (loss-making)	−73.88% (below 0%: shrinking)	n/m	−17.59% (below 0%: shrinking)	100.00%	(3,248.33%)	Compare
CLYM Climb Bio, Inc.	$626.6M	— (loss-making)	—	—	n/m	+3.73% (above 0%: growing)	—	0.00%	Compare
NVCT Nuvectis Pharma, Inc.	$618.0M	— (loss-making)	—	—	n/m	−34.57% (below 0%: shrinking)	—	0.00%	Compare
SLDB Solid Biosciences Inc.	$615.5M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−39.56% (below 0%: shrinking)	0.00%	0.00%
ZVRA Zevra Therapeutics, Inc.	$609.9M	10.5×	10.5×	+53.25% (above 0%: growing)	−88.71% (below 0%: shrinking)	+670.87% (above 0%: growing)	96.16%	42.30%	Compare
PHAT Phathom Pharmaceuticals, Inc.	$606.8M	— (loss-making)	— (loss-making)	+88.02% (above 0%: growing)	n/m	+96.86% (above 0%: growing)	79.68%	(5.34%)	Compare
OLMA Olema Pharmaceuticals, Inc.	$601.1M	— (loss-making)	—	—	n/m	−54.33% (below 0%: shrinking)	0.00%	0.00%	Compare
CRMD CorMedix Inc	$581.5M	3.0×	16.5×	+156.52% (above 0%: growing)	+13.79% (above 0%: growing)	+185.90% (above 0%: growing)	75.66%	42.10%	Compare
Median of peers	$613.9M	—	—	+53.25%	—	+39.72%	77.67%	0.00%

All 614 Biotechnology stocks →

Solid Biosciences Inc. (SLDB) key facts

Solid Biosciences Inc. (SLDB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million.
As of October 16, 2026, SLDB traded at $5.53, a market capitalization of $615.5 million.
Return on equity was −109.9% and debt-to-equity 0.00.
Its Altman Z-score is −2.87 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.